Triana MME, Rodríguez VL, Morejón RO, Quintela PAM, Pantaleón BO, García MAM

Language: Spanish
References: 26
Page:
PDF size: 111.49 Kb.

ABSTRACT

Introduction: lymphedema is a chronic illness, with rates of incidence and prevalence that are on the rise and with negative effects on the patients' quality of life.
Objective: To describe the behaviour of some biochemical parameters in patients with secondary lymphedema of the lower limbs.
Methods: a descriptive cross-sectional study conducted in 16 persons with secondary lymphedema of the lower limbs, who were detected in Cerro municipality; 10 were women (62.5 %) and six were men (37.5 %) aged 18 to 72 years. The following biochemical parameters were quantitated: glucose, total cholesterol, triglycerides, fibrinogen, and Factor VII. The behaviour of the variables were globally and individually analyzed.
Results: according to the normal limits set by the manufacturers of diagnostics, the analysis of the individual behaviour found that more than 50 % of the patients presented normal figures; values lower than the limit figures were found in total cholesterol (n=7, 43.75 %), triglycerides (n=2, 12.50 %,) and glucose (n=5, 31.25 %); however, high figures were equally observed in the case of Factor VII and fibrinogen (n=4, 25 %) respectively.
Conclusions: It may be stated that the obtained results did not allow selecting any parameter as the right marker of lymphedema, but did help to raise the level of knowledge on this poorly studied disease.

REFERENCES

1. Kerchner K, Fleischer A, Yosipovitch G. Lower extremity lymphedema update: pathophysiology, diagnosis, and treatment guidelines. J Am Acad Dermatol. 2008;59:324-31.

2. Vannelli A. A Brief Overview of Lymphology: Past, Present and Future. In: Vannelli A, editor. Novel Strategies in Lymphedema. Rijeka, Croatia: Editorial InTech; 2011. p. 1-12.

3. Rodríguez Villalonga LE. El dilema del linfedema. Rev Cubana Angiol y Cir Vasc. 2011 [citado 3 Jun 2012];12(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol12_01_11/ang11111.htm

4. Charles-Edouard D. Linfedema: Epidemiología en las Américas. Linfología. 1998;4(9):37-42.

5. Logan V. Incidence and prevalence of lymphoedema: A literature review. J Clin Nurs. 1995;4(4):213-9.

6. Moffat CJ, Franks PJ, Doherty DC. Linfedema: Un problema de salud subestimado. QJM. 2003;96:731-8.

7. Gethin G, Byrne D, Tierney S, Strapp H, Cowman S. Prevalence of lymphoedema and quality of life among patients attending a hospital-base wound management and vascular clinic. Intern Wound J. 2012;9(2):120-5.

8. Pereira de Godoy JM, Braile DM, de Fátima Godoy M, Longo O Jr. Quality of life and peripheral lymphedema. Lymphology. 2002;35(2):44-5.

9. Rodríguez Villalonga LE, Victoria García-Viniegras CR, Seuc Jo AH, Pérez Leonard D, Chirino Diaz L, Borrás Migues M. Linfedema y calidad de vida. Rev Cubana Angiol y Cir Vasc. 2012 [citado 3 Jun 2012];13(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol13_1_12/ang07112.htm

10. Mc Wayne J, Heiney SP. Psychologic and social sequelae of secondary lymphedema: A review. Cancer. 2005;104(3):457-66.

11. Rodríguez Villalonga LE, Seuc Jo AH, Lauzán Díaz E, García Lazo G, Rodríguez Álvarez M, Macías Sabuqué M. Linfedemas en el municipio Cerro. Rev Cubana Angiol y Cir Vasc. 2012 [citado 30 Sept 2012];13(2). Disponible en: http://bvs.sld.cu/revistas/ang/vol13_2_12/ang03212.htm

12. Llanes Barrios JA, Puentes Madera I, Figueredo de Armas DM, Rubio Medina Y, Valdés Pérez C. Caracterización de las afecciones vasculares en pacientes diabéticos del municipio de Jaruco. Rev Cubana Angiol Cir Vasc. 2011 [citado 3 Jun 2012];12(1)]. Disponible en: http://bvs.sld.cu/revistas/ang/vol12_01_11/ang02111.htm

13. Jull A, Walker N, Hackett M, Jones M, Rodgers A, Birchall N, et al. Leg ulceration and perceived health: a population based case-control study. Age Ageing. 2004;33:236-41.

14. Schofield M, Aziz M, Bliss M, Bull R. Medical pathology in patients with leg ulcers. J Tissue Viability. 2003;13:17-22.

15. Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F. International Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 (Supp):S5-S67.

16. Jellinger PS. Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of dyslipidaemia and Prevention of Atherogenesis. Endocrin Prac. 2000;6(2):163-213.

17. Folsom AR, Wu KK, Rosamond WR, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997;96:1102-8.

18. Lower GDO. Can haematological test predict cardiovascular risk? The 2005 Kettle Lecture. Br J Haematol. 2006;133:232-50.

19. Papendieck CM. Linfedema. Rev Asoc Méd Argent. 2006;119(1):12-5.

20. Global programme to eliminate lymphatic filariasis: progress report on mass drug administration. Wkly Epidemiol Rec. 2011;86:377-88.

21. Molyneux DH. Tropical Lymphedemas. Control and prevention. N Engl J Med. 2012;366:1169-71.

22. Lahariya C, Tomar SS. How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions. J Vect Bor Dis. 2011;48(1):1-6.

23. Meade TW. Fibrinogen measurement to assess the risk of arterial thrombosis in individual patient: yes. J Tromb Haemost. 2005;3:632-4.

24. Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation. 2004;109 (Supp IV):6-19.

25. Rudnicka AR, MT-Isa S, Meade TW. Association of plasma fibrinogen and factor VIIclotting activity with coronary heart disease and stroke: prospective cohort study from the screening phase of the Thrombosis Prevention trial. J Tromb Haemost. 2006;4(11):2405-10.

26. Lower GDO. Arterial disease and venous thrombosis: are they related, and if so what should we do about it? J Thromb Haemost. 2006;9(4):1982-5.